Thrombophilia in young women candidate to the pill: reasons for and against screening.
Screening for thrombophilia in women candidate to the pill is still a matter of debate. Oral contraceptives may trigger venous thromboembolic events in carriers of common inherited thrombophilic defects. General screening is not cost-effective from an epidemiological point of view if the objective is to prevent death due to venous thromboembolism during oral contraception (OC). However, clinicians deal with single patients and personal and/or family history for venous thromboembolism have limited value for identifying those women at risk of VTE complications during OC. A pharmacogenetics approach in prescribing OC on the basis of each woman's genetic make-up could increase drug safety. A proper evaluation of the cost-effectiveness, the medical, psychosocial and legal consequences is needed before general screening with genetic testing for inherited thrombophilia can be recommended before OC.
D000328:Adult; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects*; D005260:Female; D005820:Genetic Testing; D006801:Humans; D008403:Mass Screening; D019851:Thrombophilia / Q000175:diagnosis / Q000235:genetics / Q000517:prevention & control*
D003278:Contraceptives, Oral, Hormonal